» Articles » PMID: 23785295

PARP-1 Regulates Metastatic Melanoma Through Modulation of Vimentin-induced Malignant Transformation

Abstract

PARP inhibition can induce anti-neoplastic effects when used as monotherapy or in combination with chemo- or radiotherapy in various tumor settings; however, the basis for the anti-metastasic activities resulting from PARP inhibition remains unknown. PARP inhibitors may also act as modulators of tumor angiogenesis. Proteomic analysis of endothelial cells revealed that vimentin, an intermediary filament involved in angiogenesis and a specific hallmark of EndoMT (endothelial to mesenchymal transition) transformation, was down-regulated following loss of PARP-1 function in endothelial cells. VE-cadherin, an endothelial marker of vascular normalization, was up-regulated in HUVEC treated with PARP inhibitors or following PARP-1 silencing; vimentin over-expression was sufficient to drive to an EndoMT phenotype. In melanoma cells, PARP inhibition reduced pro-metastatic markers, including vasculogenic mimicry. We also demonstrated that vimentin expression was sufficient to induce increased mesenchymal/pro-metastasic phenotypic changes in melanoma cells, including ILK/GSK3-β-dependent E-cadherin down-regulation, Snail1 activation and increased cell motility and migration. In a murine model of metastatic melanoma, PARP inhibition counteracted the ability of melanoma cells to metastasize to the lung. These results suggest that inhibition of PARP interferes with key metastasis-promoting processes, leading to suppression of invasion and colonization of distal organs by aggressive metastatic cells.

Citing Articles

Olaparib enhancing radiosensitization and anti-metastatic effect of oral cancer by targeting IL-17A signal.

Yu C, Lin H, Chan M, Wu S, Chiou W, Lee M Cancer Cell Int. 2024; 24(1):373.

PMID: 39529064 PMC: 11552144. DOI: 10.1186/s12935-024-03547-3.


Leveraging PARP-1/2 to Target Distant Metastasis.

Frederick M, Abdesselam D, Clouvel A, Croteau L, Hassan S Int J Mol Sci. 2024; 25(16).

PMID: 39201718 PMC: 11354653. DOI: 10.3390/ijms25169032.


Investigating the Effects of Overexpression on Colorectal Cancer Cell Migration Oncolytic Virus Type 1 (oHSV-1).

Shayan S, Arashkia A, Bahramali G, Azadmanesh K Avicenna J Med Biotechnol. 2024; 16(2):120-129.

PMID: 38618508 PMC: 11007377. DOI: 10.18502/ajmb.v16i2.14863.


Molecular Frontiers in Melanoma: Pathogenesis, Diagnosis, and Therapeutic Advances.

Kim H, Kim Y Int J Mol Sci. 2024; 25(5).

PMID: 38474231 PMC: 10931637. DOI: 10.3390/ijms25052984.


PARP inhibition and immunotherapy: a promising duo in fighting cancer.

Phillipps J, Zhou A, Butt O, Ansstas G Transl Cancer Res. 2023; 12(9):2433-2437.

PMID: 37859734 PMC: 10583004. DOI: 10.21037/tcr-23-726.


References
1.
Fidler I . Selection of successive tumour lines for metastasis. Nat New Biol. 1973; 242(118):148-9. DOI: 10.1038/newbio242148a0. View

2.
Schreiber V, Dantzer F, Ame J, de Murcia G . Poly(ADP-ribose): novel functions for an old molecule. Nat Rev Mol Cell Biol. 2006; 7(7):517-28. DOI: 10.1038/nrm1963. View

3.
Hsu M, Andl T, Li G, Meinkoth J, Herlyn M . Cadherin repertoire determines partner-specific gap junctional communication during melanoma progression. J Cell Sci. 2000; 113 ( Pt 9):1535-42. DOI: 10.1242/jcs.113.9.1535. View

4.
Gilles C, Polette M, Mestdagt M, Nawrocki-Raby B, Ruggeri P, Birembaut P . Transactivation of vimentin by beta-catenin in human breast cancer cells. Cancer Res. 2003; 63(10):2658-64. View

5.
Fong P, Boss D, Yap T, Tutt A, Wu P, Mergui-Roelvink M . Inhibition of poly(ADP-ribose) polymerase in tumors from BRCA mutation carriers. N Engl J Med. 2009; 361(2):123-34. DOI: 10.1056/NEJMoa0900212. View